About CLS Investment Criteria Our Team Scientific Advisors Portfolio News Contact
 
 
     
 

XLumena Spots $6M For Ultrasound Devices
June 4, 2008


Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
APRIL 28, 2008


Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors
APRIL 25, 2008


EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients
February 26, 2008


KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing
February 20, 2008


EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
January 8, 2008


EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity
January 7, 2008


CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy
January 7, 2008


APT Pharmaceuticals Expands Management Team
NOVEMBER 19, 2007


EnteroMedics Announces Initial Public Offering
NOVEMBER 14, 2007


APT Pharmaceuticals Closes New $22 Million Funding Round
OCTOBER 4, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
SEPTEMBER 20, 2007


Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids
AUGUST 21, 2007


KFx Medical Corporation Closes $10 Million Series B Financing
AUGUST 9, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
JUNE 18, 2007


CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President
JUNE 6, 2007


APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection
JUNE 5, 2007


Enteromedics Files Registration Statement
for Proposed Initial Public Offering
MAY 25, 2007


CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
APRIL 10, 2007


Athenagen Announces Name Change to CoMentis
FEBRUARY 10, 2007


Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study
JANUARY 31, 2007


Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease
DECEMBER 13, 2006


Mirabilis Medica Names Mike Connolly CEO
OCTOBER 3, 2006


Athenagen Raises $50 Million in Series B Financing
SEPTEMBER 28, 2006


Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents
SEPTEMBER 26, 2006


Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids
AUGUST 29, 2006


Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD
AUGUST 21, 2006


Athenagen Completes Merger with Zapaq
AUGUST 14, 2006


KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation
AUGUST 10, 2006


Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia
JUNE 15, 2006


Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline
APRIL 13, 2006


Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
MARCH 23, 2006


Athenagen Adds A. Barr Dolan to its Board of Directors
FEBRUARY 22, 2006


Previous News Stories >

 
     
 

CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy

South San Francisco, CA – april 10, 2007

CoMentis, Inc. (formerly Athenagen), a privately held biopharmaceutical company, announced today the initiation of a Phase II clinical study of ATG3, the company’s topical eye drop therapy for neovascular age-related macular degeneration (NV-AMD). A proprietary ophthalmic formulation of mecamylamine, ATG3 is an antagonist of the nicotinic acetylcholine (nACh) receptor pathway that mediates angiogenesis. The drug was developed to effectively penetrate into the retina and choroid following topical eye drop administration.

This Phase II study is a double-masked, randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of ATG3 in patients with NV-AMD (also known as “wet’ AMD). Approximately 330 patients will be randomized to one of three treatment groups, administered by eye drop twice daily: two different doses of ATG3 or placebo. One eye per patient will receive the study treatment. All patients will be treated for up to 48 weeks, during which time they will be monitored for safety, tolerability and efficacy assessments. Patients will be assessed for change in visual acuity and macular thickness using ocular coherence tomography.

“In January we completed our Phase I study of ATG3 in healthy volunteers and found excellent ocular safety following eye drop administration,” said Henry Hsu, M.D., Chief Medical Officer of CoMentis. “We are very pleased to begin this international Phase II study as planned, and expect to have interim (six month) efficacy data by mid-2008. ATG3 could be the first topical angiogenic treatment for AMD and if approved, would compliment current therapies which require injection directly into the eye.” Inhibition of the nicotinic acetylcholine (nACh) receptor pathway, which was discovered at Stanford by two of CoMentis’s founding scientists, also down regulates vascular endothelial-derived growth factor (VEGF) dependent angiogenesis. Studies in animal models have demonstrated excellent penetration of the proprietary ATG3 formulation to the retina and choroid following eye drop application as well as reduction of new blood vessel growth in the eye.

About AMD
AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, the light-sensitive tissue at the back of the eye. These new blood vessels tend to be very fragile and often leak blood and fluid. The blood and fluid raise the macula from its normal place at the back of the eye and lead to loss of central vision, often quite rapidly. Although it rarely causes total blindness, AMD robs those affected of their sharp central vision required for most daily visual activities. It destroys the clear, “straight ahead” central vision necessary for reading, driving, identifying faces, watching television, doing fine detailed work, safely navigating stairs and performing other daily tasks. Approximately two million patients in the U.S. suffer from neovascular AMD and this number is expected to grow with an aging population.

 

About CoMentis
CoMentis, Inc. has its headquarters in South San Francisco, with research operations in both South San Francisco and Oklahoma City. The company is engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders. The company has two fundamental technology platforms: (i) aspartic protease inhibitors, including beta-secretase inhibitors for Alzheimer’s disease; and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.

Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following the August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise. Zapaq was founded in 2001 by Jordan Tang, Ph.D., of the Oklahoma Medical Research Foundation, and Arun Ghosh, Ph.D., now at Purdue University, both experts in the field of aspartic proteases. Dr. Tang's groundbreaking discovery of beta-secretase, an aspartic protease which is a critical enzyme in beta amyloid production, was published in Proceedings of the National Academy of Sciences in 2000.

CoMentis currently has three product development programs based on its two technologies: ATG-3, a topical (eye drop) anti-angiogenesis compound for neovascular AMD; CTS-21166, an orally active beta-secretase inhibitor for Alzheimer’s disease; and GTS-21, an oral agonist of the alpha-7 nACh receptor pathway for cognition enhancement.

For more information: www.comentis.com

 

CONTACT COMENTIS:
W. Scott Harkonen
M.D,President & CEO
Office (650) 869-7600
press@comentis.com


 
     
     
   
 
 
© 2006 CHARTER LIFE SCIENCES